Close Menu

NEW YORK ─ The US Food and Drug Administration in February granted 510(k) clearances for tests from DiaSorin, Roche Diagnostics, and Inova Diagnostics, according to the agency's website.

DiaSorin nabbed a clearance for its Liaison Anti-HAV chemiluminescent immunoassay to detect total antibodies to the hepatitis A virus in serum and plasma samples. The laboratory-based test, performed on DiaSorin's Liaison analyzers, detects current or previous hepatitis A infections and the presence of an antibody response to the hepatitis A virus in vaccine recipients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.